167 related articles for article (PubMed ID: 1643698)
1. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Bailey H; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Grem JL; Spriggs DR
Cancer Chemother Pharmacol; 1992; 30(4):297-302. PubMed ID: 1643698
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
Remick SC; Grem JL; Fischer PH; Tutsch KD; Alberti DB; Nieting LM; Tombes MB; Bruggink J; Willson JK; Trump DL
Cancer Res; 1990 May; 50(9):2667-72. PubMed ID: 2328492
[TBL] [Abstract][Full Text] [Related]
3. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
4. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
5. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
6. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Köhne CH; Hiddemann W; Schüller J; Weiss J; Lohrmann HP; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
J Clin Oncol; 1995 May; 13(5):1201-8. PubMed ID: 7738622
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
8. Leucovorin + 5-fluorouracil plus dipyridamole in leucovorin + 5-fluorouracil-pretreated patients with advanced colorectal cancer: a pilot study of three different dipyridamole regimens.
Tsavaris N; Kosmas C; Polyzos A; Genatas K; Vadiaka M; Paliaros P; Dimitrakopoulos A; Rokana S; Karatzas G; Vachiotis P; Fotiadis K
Tumori; 2001; 87(5):303-7. PubMed ID: 11765178
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.
Bjarnason GA; Kerr IG; Doyle N; Macdonald M; Sone M
Cancer Chemother Pharmacol; 1993; 33(3):221-8. PubMed ID: 8269603
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin.
Arbuck SG; Douglass HO; Trave F; Rustum YM
NCI Monogr; 1987; (5):203-5. PubMed ID: 3501544
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
14. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.
Danhauser LL; Freimann JH; Gilchrist TL; Gutterman JU; Hunter CY; Yeomans AC; Markowitz AB
J Clin Oncol; 1993 Apr; 11(4):751-61. PubMed ID: 8478667
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
16. Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies.
Bruckner HW; Petrelli NJ; Stablein D; Novak J; Mayer R
NCI Monogr; 1987; (5):179-84. PubMed ID: 3501539
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid.
Budd GT; Jayaraj A; Grabowski D; Adelstein D; Bauer L; Boyett J; Bukowski R; Murthy S; Weick J
Cancer Res; 1990 Nov; 50(22):7206-11. PubMed ID: 2224854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
